^
Association details:
| Biomarker: | PD-L1 overexpression + TMB-L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.01-017 - Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer
Published date:
07/12/2022
Excerpt:
Patients with high PD-L1 (≥50%), low cfDNA at C0 (cutoff: 8.6 ng/mL) or decreased bTMB from C0 to C4/EOT showed significant PFS benefit (p<0.05)...In previously treated NSCLC patients, improvement in treatment efficacy of atezolizumab was correlated with high PD-L1 expression and serial decrease in bTMB suggesting that PD-L1 expression combined with bTMB could be predictive for atezolizumab benefit.
